Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 685509 alone or with empagliflozin for portal hypertension in compensated cirrhosis
2021-005171-40Phase 2Active
- Sponsor
- Boehringer Ingelheim
- Start
- Feb 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in Portal Hypertension (PH) and Cirrhosis comparing BI 685509 monotherapy with BI 685509 + Jardiance (2 arms). Primary endpoint: Percentage change in HVPG from baseline after 8 weeks. Started Feb 2022; status: active.
02
Drugs
avenciguatempagliflozin
03
Conditions
Portal Hypertension (PH)Cirrhosis
Beyond the preview
Go deeper on 2021-005171-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-005171-40.